Lv4
450 积分 2025-12-23 加入
A Health Policy Model of CKD: 1. Model Construction, Assumptions, and Validation of Health Consequences
4个月前
已完结
Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis
4个月前
已完结
Cost-effectiveness analysis of empagliflozin as an add-on to the standard of care for chronic kidney disease management in the Philippines
5个月前
已完结
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
7个月前
已完结
Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial
7个月前
已完结
Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial
7个月前
已完结
Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care
8个月前
已完结
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial
8个月前
已关闭
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
8个月前
已完结
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
8个月前
已关闭
皖公网安备34019202002308
